Literature DB >> 33627769

MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.

Wenrui Duan1,2,3, Shirley Tang4, Li Gao5, Kathleen Dotts4, Andrew Fink4, Arjun Kalvala4, Brittany Aguila4, Qi-En Wang6, Miguel A Villalona-Calero7,8.   

Abstract

The Fanconi Anemia (FA) pathway is essential for human cells to maintain genomic integrity following DNA damage. This pathway is involved in repairing damaged DNA through homologous recombination. Cancers with a defective FA pathway are expected to be more sensitive to cross-link based therapy or PARP inhibitors. To evaluate downstream effectors of the FA pathway, we studied the expression of 734 different micro RNAs (miRNA) using NanoString nCounter miRNA array in two FA defective lung cancer cells and matched control cells, along with two lung tumors and matched non-tumor tissue samples that were deficient in the FA pathway. Selected miRNA expression was validated with real-time PCR analysis. Among 734 different miRNAs, a cluster of microRNAs were found to be up-regulated including an important cancer related micro RNA, miR-200C. MiRNA-200C has been reported as a negative regulator of epithelial-mesenchymal transition (EMT) and inhibits cell migration and invasion by promoting the upregulation of E-cadherin through targeting ZEB1 and ZEB2 transcription factors. miRNA-200C was increased in the FA defective lung cancers as compared to controls. AmpliSeq analysis showed significant reduction in ZEB1 and ZEB2 mRNA expression. Our findings indicate the miRNA-200C potentially play a very important role in FA pathway downstream regulation.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33627769      PMCID: PMC7904768          DOI: 10.1038/s41598-021-83884-9

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  52 in total

1.  Regulation of Fanconi anemia protein FANCD2 monoubiquitination by miR-302.

Authors:  Bharathi Suresh; A Madhan Kumar; Hoe-Su Jeong; Youl-Hee Cho; Suresh Ramakrishna; Kye-Seong Kim
Journal:  Biochem Biophys Res Commun       Date:  2015-09-03       Impact factor: 3.575

2.  Biallelic mutations in the ubiquitin ligase RFWD3 cause Fanconi anemia.

Authors:  Kerstin Knies; Shojiro Inano; María J Ramírez; Masamichi Ishiai; Jordi Surrallés; Minoru Takata; Detlev Schindler
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

3.  A novel ubiquitin ligase is deficient in Fanconi anemia.

Authors:  Amom Ruhikanta Meetei; Johan P de Winter; Annette L Medhurst; Michael Wallisch; Quinten Waisfisz; Henri J van de Vrugt; Anneke B Oostra; Zhijiang Yan; Chen Ling; Colin E Bishop; Maureen E Hoatlin; Hans Joenje; Weidong Wang
Journal:  Nat Genet       Date:  2003-09-14       Impact factor: 38.330

4.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Authors:  Sun-Mi Park; Arti B Gaur; Ernst Lengyel; Marcus E Peter
Journal:  Genes Dev       Date:  2008-04-01       Impact factor: 11.361

5.  MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.

Authors:  Wenrui Duan; Li Gao; Xin Wu; Li Wang; Serge P Nana-Sinkam; Gregory A Otterson; Miguel A Villalona-Calero
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

6.  MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator.

Authors:  Aihong Jiao; Minghua Sui; Liangming Zhang; Ping Sun; Dongmei Geng; Weiwei Zhang; Xiuwen Wang; Junxia Li
Journal:  Mol Med Rep       Date:  2016-02-17       Impact factor: 2.952

7.  miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

Authors:  Liana Adam; Meng Zhong; Woonyoung Choi; Wei Qi; Milena Nicoloso; Ameeta Arora; George Calin; Hua Wang; Arlene Siefker-Radtke; David McConkey; Menashe Bar-Eli; Colin Dinney
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

8.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

9.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

Review 10.  DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway.

Authors:  Sonali Bhattacharjee; Saikat Nandi
Journal:  Cell Commun Signal       Date:  2017-10-10       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.